Nuplazid Can Treat Psychosis in Alzheimer’s Patients But Benefit Only Seen in Short Term, Study Reports

Nuplazid Can Treat Psychosis in Alzheimer’s Patients But Benefit Only Seen in Short Term, Study Reports
Results from a Phase 2 clinical trial show that Nuplazid (pimavanserin) can safely treat, but possibly in the short-term only, symptoms of psychosis in Alzheimer’s patients, a study looking at data from that U.K. trial reports. An accompanying commentary, however, raised concerns about the clinical meaningfulness of these results and findings of safety. More studies are now underway. The research, “Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study,” appeared in the journal
Subscribe or to access all post and page content.